INC Research/inVentiv Health Strengthens Leadership of Commercial Solutions


RALEIGH, N.C., Dec. 07, 2017 (GLOBE NEWSWIRE) -- INC Research/inVentiv Health (NASDAQ:INCR), the only fully integrated biopharmaceutical solutions organization combining a CRO and a CCO (Contract Commercial Organization), today announced that Michelle Keefe has been appointed President, Commercial Solutions, effective December 1, 2017, succeeding Michael Bell. Bell will continue as Chairman of the Board of Directors.

In overseeing Commercial Solutions, Keefe will be responsible for driving growth and performance for the Company’s industry-leading commercialization capabilities. She joins INC Research/inVentiv Health with more than 25 years of experience in the life sciences industry, serving both for-profit and non-profit organizations. Keefe previously served as Global Group President and Chief Development Officer, Publicis Health, where she had responsibility for the Contract Sales Organization (CSO), clinical affairs, business development and specialty agency functions. During her tenure at Publicis, she doubled topline business growth while identifying significant operational efficiencies. Before joining Publicis Health, Keefe was Vice President, Business Development with The Visiting Nurse Service of New York, the largest not-for-profit homecare provider in the United States. Prior to that, she spent more than 20 years rising through the ranks at Pfizer where she served in numerous positions of increasing responsibility culminating as regional president.

Alistair Macdonald, Chief Executive Officer of INC Research/inVentiv Health, said, “I am thrilled to welcome Michelle to oversee and drive INC Research/inVentiv Health’s market-leading commercial offering. Michelle is a recognized leader whose unique qualifications and experience will enable us to deliver strong and consistent revenue growth across our commercial portfolio and capitalize on the substantial potential of the commercial market. With Michelle’s appointment we are poised to reignite long-term growth of our higher-margin offerings.”

“I am excited and honored to join the talented team at INC Research/inVentiv Health. As the commercialization model continues to evolve, there’s significant opportunity to leverage our industry-leading portfolio to serve both large pharma and the untapped small- and mid-sized market,” said Keefe. “Customers now require flexible, targeted programs that complement traditional outsourced sales representatives with medical science liaisons (MSLs), reimbursement specialists and sophisticated market access and multi-channel capabilities. INC Research/inVentiv Health has the people, perspectives and programs to deliver these new solutions. Coupled with our ability to tap insights generated earlier in the clinical trial process, it’s a powerful platform designed to produce a higher likelihood of launch success.”

About INC Research/inVentiv Health
INC Research/inVentiv Health (Nasdaq:INCR) is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to address new market realities where clinical and commercial share expertise, data and insights to accelerate biopharmaceutical performance. With more than 22,000 employees and the ability to support customers in more than 110 countries, its global scale and deep therapeutic alignment enables INC Research/inVentiv Health to help customers successfully navigate an increasingly complex environment. For more information, visit or

Cautionary Statement Regarding Forward-Looking Statements
Except for historical information, all of the statements, expectations, and assumptions contained in this press release are forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include, but are not limited to: risks associated with the integration of our business with the business of inVentiv, and our operation of the combined business following the closing of the Merger; our ability to maintain or generate new business awards; our ability to increase our market share, grow our business, and execute our growth strategies; our backlog not being indicative of future revenues and our ability to realize the anticipated future revenue reflected in our backlog; our ability to adequately price our contracts and not overrun cost estimates; general and international economic, political, and other risks, including currency and stock market fluctuations and the uncertain economic environment; fluctuations in our financial results; reliance on key personnel; our customer or therapeutic area concentration; and the other risk factors set forth in our Form-Q for the quarter ended September 30, 2017, and other SEC filings, copies of which are available free of charge on our website at INC Research assumes no obligation and does not intend to update these forward-looking statements, except as required by law.


Investor Relations:
Ronnie Speight
Vice President, Investor Relations
+1 919 745 2745

Danielle DeForge
Senior Director, External Communications
+1 781 425 4624


Back to news